Lin YeunYi, McCrimmon Rory J, Pearson Ewan R
School of Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, Scotland.
Diabet Med. 2025 Mar;42(3):e15469. doi: 10.1111/dme.15469. Epub 2025 Jan 11.
Type 2 diabetes (T2D) is a complex condition characterised by the interaction between insulin resistance and beta cell dysfunction. C-peptide, a key biomarker of endogenous insulin secretion, has a role in diagnosing type 1 diabetes (T1D). However, its utility in T2D has not been extensively studied. This review provides an overview of the progression of C-peptide levels over time in T2D and discuss its interpretation in clinical settings. We reviewed current evidence on the relationship between C-peptide levels and response to antidiabetic drugs, as well as the utility of C-peptide testing in T2D treatment strategies. We also reviewed available evidence for C-peptide in predicting future outcomes in T2D. In this review, we hoped to clarify the value of C-peptide testing in understanding and managing T2D and to highlight areas where further research is needed.
2型糖尿病（T2D）是一种复杂的病症，其特征在于胰岛素抵抗和β细胞功能障碍之间的相互作用。C肽是内源性胰岛素分泌的关键生物标志物，在1型糖尿病（T1D）的诊断中发挥作用。然而，其在T2D中的效用尚未得到广泛研究。本综述概述了T2D中C肽水平随时间的变化，并讨论其在临床环境中的解读。我们回顾了关于C肽水平与抗糖尿病药物反应之间关系的现有证据，以及C肽检测在T2D治疗策略中的效用。我们还回顾了C肽在预测T2D未来结局方面的现有证据。在本综述中，我们希望阐明C肽检测在理解和管理T2D中的价值，并突出需要进一步研究的领域。
